The Journal of clinical endocrinology and metabolism
-
J. Clin. Endocrinol. Metab. · Mar 2014
Randomized Controlled TrialVitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial.
Low 25-hydroxyvitamin D levels are common in patients with primary hyperparathyroidism (PHPT) and associated with higher PTH levels and hungry bone syndrome after parathyroidectomy (PTX). However, concerns have been raised about the safety of vitamin D supplementation in PHPT. ⋯ Daily supplementation with a high vitamin D dose safely improves vitamin D status and decreases PTH in PHPT patients. The vitamin D treatment is accompanied by reduced bone resorption and improved bone mineral density before operation.
-
J. Clin. Endocrinol. Metab. · Mar 2014
Randomized Controlled TrialGlucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Patients with type 2 diabetes mellitus (T2DM) have clinically relevant disturbances in the effects of the hormone glucose-dependent insulinotropic polypeptide (GIP). ⋯ In patients with T2DM, GIP counteracts insulin-induced hypoglycemia, most likely through a predominant glucagonotropic effect. In contrast, during hyperglycemia, GIP increases glucose disposal through a predominant effect on insulin release.
-
J. Clin. Endocrinol. Metab. · Mar 2014
Review Meta AnalysisEfficacy of vitamin D supplementation in depression in adults: a systematic review.
Randomized controlled trials (RCTs) investigating the efficacy of vitamin D (Vit D) in depression provided inconsistent results. ⋯ There is insufficient evidence to support the efficacy of Vit D supplementation in depression symptoms, and more RCTs using depressed patients are warranted.
-
J. Clin. Endocrinol. Metab. · Mar 2014
Randomized Controlled Trial Multicenter Study Comparative StudyPasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control. ⋯ Pasireotide LAR demonstrated superior efficacy over octreotide LAR and is a viable new treatment option for acromegaly.
-
J. Clin. Endocrinol. Metab. · Mar 2014
Multicenter StudyLong-term follow-up in adrenal incidentalomas: an Italian multicenter study.
The long-term consequences of subclinical hypercortisolism (SH) in patients with adrenal incidentalomas (AIs) are unknown. ⋯ SH is associated with the risk of incident CVEs. Besides the clinical follow-up, in patients with an AI >2.4 cm, a long-term biochemical follow-up is also required because of the risk of SH development.